There is a fundamental gap in understanding the extent to which treatment of bacterial biofilms with combinations of drug compounds may synergistically kill the biofilm colonies. Continued existence of this gap represents an important problem because, until it is filled, the development of co-therapy systems for clinical use in chronic infections will be delayed. The long term goal of this research is to develop novel and effective inhalable strategies for the treatment of respiratory infections. The objective in this application is to identify compounds that, when delivered in combination, more effectively eradicate Pseudomonas aeruginosa biofilms. Our central hypothesis is that delivery of selected dispersion compounds will increase the sensitivity of P. aeruginosa to antibiotic treatment, resulting in improved outcomes in a murine model. This hypothesis has been formulated on the basis of preliminary data produced in the applicants'laboratories. Once it is known which combinations of compounds can synergistically enhance biofilm killing in vitro and in vivo, new treatment strategies based on these compounds can be clinically developed. The proposed research is innovative because it focuses on enhancing the effectiveness of traditional antibiotics with the use of dispersion compounds that target disruption of the biofilm. The proposed research is significant because it is expected to provide knowledge needed for the clinical development of inhalable co-delivery aerosols for the treatment of bacterial biofilms.

Public Health Relevance

The proposed research is relevant to public health because the discovery and development of new therapies to eradicate respiratory biofilms is ultimately expected to improve the quality of life of affected patients and limit the ability of these bacteri to become resistant to antimicrobial therapy. This is relevant to the part of NIH's mission that pertains to the application of fundamental knowledge that will reduce burden of illness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI096007-02
Application #
8646867
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Taylor, Christopher E,
Project Start
2013-04-15
Project End
2015-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
Schools of Pharmacy
DUNS #
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Sommerfeld Ross, S; Gharse, S; Sanchez, L et al. (2017) Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication. Int J Pharm 531:14-23
Gharse, Sachin; Fiegel, Jennifer (2016) Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery. Curr Pharm Des 22:2463-9
Sommerfeld Ross, Stacy; Tu, Mai Han; Falsetta, Megan L et al. (2014) Quantification of confocal images of biofilms grown on irregular surfaces. J Microbiol Methods 100:111-20